Yingbei Chen
Overview
Explore the profile of Yingbei Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
1232
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fitzgerald K, Lee C, Voss M, Carlo M, Knezevic A, Peralta L, et al.
Eur Urol
. 2024 Oct;
87(1):96.
PMID: 39426859
No abstract available.
2.
Eismann L, Zucker M, Dawidek M, Reese S, Calderon L, Aulitzky A, et al.
Urol Pract
. 2024 Jun;
11(5):860-870.
PMID: 38913557
Introduction: Oncological outcomes in patients with nonclear cell renal cell carcinoma (non-ccRCC) treated with surgery for locoregional nodal disease (ND) remain incompletely characterized. The objective was to investigate the characteristics...
3.
Fitzgerald K, Lee C, Voss M, Carlo M, Knezevic A, Peralta L, et al.
Eur Urol
. 2024 May;
86(2):90-94.
PMID: 38782695
Treatment options are limited for patients with non-clear cell renal cell carcinoma (nccRCC). Patients with nccRCC experienced a favorable objective response rate (ORR) in a phase 2 trial of cabozantinib...
4.
Kotecha R, Doshi S, Knezevic A, Chaim J, Chen Y, Jacobi R, et al.
Eur Urol Oncol
. 2023 Nov;
7(4):804-811.
PMID: 37945488
Background: Although different kidney cancers represent a heterogeneous group of malignancies, multiple subtypes including Von Hippel-Lindau (VHL)-altered clear cell renal cell carcinoma (ccRCC), fumarate hydratase (FH)- and succinate dehydrogenase (SDH)-deficient...
5.
Nezami B, Modak S, Cardenas F, Sarungbam J, Sirintrapun S, Gopalan A, et al.
Pediatr Blood Cancer
. 2023 May;
70(8):e30434.
PMID: 37243318
Background: Ganglioneuroblastoma intermixed (GNBI) is classified as "favorable" histology by International Neuroblastoma Pathology Classification system. However, the International Neuroblastoma Risk Group (INRG) stratifies patients using wider clinicopathological and cytogenetic/molecular parameters....
6.
Liu M, Kuo F, Capistrano K, Kang D, Nixon B, Shi W, et al.
Nature
. 2020 Oct;
587(7832):115-120.
PMID: 33087928
The immune system uses two distinct defence strategies against infections: microbe-directed pathogen destruction characterized by type 1 immunity, and host-directed pathogen containment exemplified by type 2 immunity in induction of...
7.
Dogan S, Cotzia P, Ptashkin R, Nanjangud G, Xu B, Momeni Boroujeni A, et al.
Hum Pathol
. 2020 Aug;
104:105-116.
PMID: 32818509
SMARCB1-deficient sinonasal carcinoma (SNC) is an aggressive malignancy characterized by INI1 loss mostly owing to homozygous SMARCB1 deletion. With the exception of a few reported cases, these tumors have not...
8.
Shantharam G, Huang C, Singla N, Chen Y, Russo P
Urology
. 2019 Oct;
135:e2-e4.
PMID: 31593703
Primary renal neuroendocrine tumors (NETs) are exceedingly rare with roughly 100 reported cases. To the best of our knowledge, this is the first reported case of a primary renal NET...
9.
Gupta S, Vanderbilt C, Cotzia P, Arias Stella 3rd J, Chang J, Chen Y, et al.
Hum Pathol
. 2018 Sep;
88:87-91.
PMID: 30236595
As immune checkpoint inhibitors are rapidly developing into the standard of care for patients with advanced melanoma, the value of diagnostic metrics to predict response to immunotherapy is steadily increasing....
10.
Casuscelli J, Becerra M, Manley B, Zabor E, Reznik E, Redzematovic A, et al.
Eur Urol Focus
. 2017 Sep;
5(4):642-649.
PMID: 28951115
Background: Mutations in the promoter region of the TERT gene have been detected in a variety of cancers. These mutations can potentially lead to unlimited cell divisions and result in...